CA-CROWN-BIOSCIENCE
7.10.2021 14:32:07 CEST | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company and leader in translational services that help biopharmaceutical companies accelerate new drug development programs, today announced the launch of its ‘3D Ex Vivo Patient Tissue Platform’. Using freshly collected patient tumor material, this new service can accurately measure oncology and immuno-oncology drug-induced tumor killing and endogenous immune cell proliferation in a high throughput format. Researchers are presenting data on the new platform at this year’s AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , which is happening virtually on October 7-10, 2021.
The proprietary technology, developed at Crown Bioscience’s recently acquired site in Leiden, The Netherlands (formerly known as OcellO B.V.), aims to improve clinical success rates by using the most patient-relevant tumor samples to better predict tumor response to potential drug candidates.
“Our goal is to leverage our core technologies to build a translational model system that adequately captures the tumor architecture and microenvironment, and improves the predictability of patient responses to treatment protocols for existing and potential therapeutic candidates,” said Leo Price, PhD, Senior Vice President, In Vitro . “We believe this approach provides greater translational relevance in drug development by using immuno-competent primary human tumor tissue to help analyze drug candidate responses before the program enters clinical trial. This approach is an optimal fit with our mission to help deliver the right drug to the right patient at the right time.”
The ‘3D Ex Vivo Patient Tissue Platform’ utilizes patient tumor tissue isolated from biopsies, surgical resections, ascites, or pleural effusion samples that are processed within 24 hours to preserve the tumor microenvironment. The automated high throughput platform uses high content 3D imaging and image analysis to quantify distinct responses of individual cell populations in fresh patient tissues. These analyses can assess responses to different doses of therapeutic candidates at various timepoints and can determine the effects of the drug or combination of drugs on tumor killing and immune cell proliferation.
“We believe this new service can help fill a critical gap in today’s research landscape with early translational patient-relevant ex vivo models that can assess efficacy and determine mechanisms of action,” commented Armin Spura, PhD, Chief Executive Officer of Crown Bioscience . “This new service offering is designed to help mitigate the high failure rates of clinical programs in oncology, and was one of the objectives coming out of our recent OcellO acquisition. We are delighted to provide immediate value to our customers from this investment and look forward to the future value that this acquisition will bring.”
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Researchers from CrownBio are conducting a poster presentation titled, “Novel Near Vivo Drug Response Platform for Oncology using 3D Ex Vivo Patient-Derived Microtumors” at the annual conference. The poster summarizes:
- This 3D high content assay on ex vivo patient tumor material preserves native tumor microenvironement and architecture
- Ex vivo testing using ultra fresh patient tumor samples maintains intact endogenous immune cell populations
- Ongoing clinical trial collaborations with tissue providers for ovarian cancer, bladder cancer, NSCLC, and other tumor samples
For more information on Crown Bioscience’s 3D Ex Vivo Patient Tissue Platform, visit Crown Bioscienes's webpage on the new service.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology, immuno-oncology, and immune mediated inflammatory disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIKE, Inc. Announces Planned CFO Transition23.6.2026 22:17:00 CEST | Press release
David M. Denton named incoming Chief Financial Officer NIKE, Inc. (NYSE:NKE) today announced that David M. Denton will join the company as Executive Vice President and Chief Financial Officer, effective August 17. Matthew Friend will step down as Executive Vice President and Chief Financial Officer at that time and remain with the company through September 4 to support an orderly transition. Friend will participate in the company’s fourth quarter fiscal 2026 earnings call on June 30, as planned. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623328558/en/ David M. Denton | Incoming Executive Vice President & Chief Financial Officer, NIKE, Inc. Denton will lead Nike’s global finance organization, partnering with President and Chief Executive Officer Elliott Hill and the Senior Leadership Team to support disciplined execution, capital allocation, and long-term value creation. “Dave is a proven public-company CFO who knows h
Grid Dynamics Hosted XT26, Convening Capital Markets Technology Leaders on the Volatility of AI in Financial Services23.6.2026 22:05:00 CEST | Press release
Key Takeaways: Grid Dynamics hosted XT26, an invite-only forum focused on the volatility of AI in financial services. XT26 attendees and speakers included over 250 senior technology leaders from global financial institutions such as Bank of America, Citi, HSBC, UBS, JP Morgan, Morgan Stanley, and others. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, hosted XT26. The invite-only conference convened over 250 senior technology leaders from banking, hedge funds, and capital markets at Tower Hill, London. Now in its 10th year, the XT conference series has grown into one of financial services engineering's most respected peer forums in London, built on a single premise: pure thought leadership grounded in real-world experience, with no sales pitches, and no vendor presentations. Just practitioners who are actually doing the work. This press release features multimedia. View the full release here: https://www.businessw
Thales Secures Significant U.S. Army LOCODA Radio Order Following Rapid Development Push23.6.2026 19:42:00 CEST | Press release
The U.S. Army has selected the Thales Radio Adaptable Transport (RAT) to support the Service’s Low Cost Data Architecture (LOCODA) tactical communications transformation effort. Rapidly developed and production ready, LOCODA RAT delivers scalable, modular, multi-transport voice and data connectivity designed to support evolving operational requirements across current and future mounted platforms. Built on a commercial-off-the-shelf and non-developmental item approach, LOCODA RAT scales production, supports continuous upgrades, and reduces integration complexity and lifecycle costs. Delivering capability at mission speed, Thales subsidiary, Thales Defense & Security, Inc. (TDSI), has secured an order for up to 5,000 Low Cost Data Architecture (LOCODA) Radio Adaptable Transport (RAT) platforms. The Thales RAT solution, which was conceived, developed and field-ready less than four months, modernizes voice and data communications and integrates effortlessly into radio mounts across all cur
Epicor Prism Launches Across European Markets, Bringing Embedded, Industry-Specific AI to Manufacturers23.6.2026 17:55:00 CEST | Press release
New AI capabilities help organisations enhance operational decision-making Epicor has expanded its AI-driven ERP strategy in the UK and select European markets with the general availability of Epicor Prism, a portfolio of vertical AI agents designed specifically for the supply chain industries. Embedded directly in Epicor Kinetic, Epicor Prism gives customers conversational access to live ERP data and related documents without needing specialised analytics skills or separate AI tools. The launch reflects a broader shift in ERP from systems of record to systems of outcomes that help users interpret data, make decisions and take action in real time — a transformation Epicor calls Cognitive ERP. Responding to pressure on productivity and skills European manufacturers are under growing pressure to raise productivity, strengthen supply chain resilience and remain globally competitive despite workforce constraints and ongoing digital skills shortages. While many organisations continue to inv
Airship Appoints Laura Zwahlen as Chief Revenue Officer23.6.2026 17:00:00 CEST | Press release
Go-To-Market and Revenue Operations Veteran to Lead Global Sales and Customer Success Organizations into the Next Phase of Growth Airship, the mobile-first customer experience company, today announced the appointment of Laura Zwahlen as Chief Revenue Officer (CRO). Zwahlen will oversee all global revenue-generating activities, driving the alignment, execution, and strategy across Airship’s sales, account management, and customer success teams to accelerate the company’s market leadership and customer impact. She will report directly to CEO Brett Caine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623145620/en/ Laura Zwahlen, Chief Revenue Officer (CRO) of Airship Zwahlen brings more than 20 years of go-to-market and revenue leadership experience, with a proven track record of guiding technology organizations through rapid growth, strategic acquisitions, and public offerings. Previously, she served as CRO at NextRoll (th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom